AN2 Therapeutics director granted 1,192 shares

AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of common stock as part of non-employee director compensation.

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. director Patricia A. Martin received a grant of common stock as part of non-employee director compensation. She acquired 1,192 shares at a price of $0.00 per share, issued in lieu of cash fees, and now directly holds 18,097 shares. According to the disclosure, all of the awarded shares vest immediately.

Insider Trade Summary

Grant/Award: 1,192 shares

Grant/Award 1 txn

Insider Martin Patricia A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,192	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,097 shares (Direct)

Footnotes (1)

1. F1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

Key Figures

Shares granted: 1,192 shares Grant price: $0.00 per share Shares owned after: 18,097 shares

3 metrics

Shares granted 1,192 shares Common stock grant under non-employee director compensation policy

Grant price $0.00 per share Equity issued in lieu of cash compensation

Shares owned after 18,097 shares Direct holdings following the reported grant

Key Terms

non-employee director compensation policy, issued in lieu of cash compensation, vest immediately, grant, award, or other acquisition

4 terms

non-employee director compensation policy financial

"under the issuer's non-employee director compensation policy"

issued in lieu of cash compensation financial

"Represents shares issued in lieu of cash compensation"

vest immediately financial

"All shares vest immediately"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AN2 Therapeutics (ANTX) director Patricia A. Martin report on this Form 4?

Patricia A. Martin reported receiving 1,192 shares of AN2 Therapeutics common stock as a grant. The shares were issued instead of cash under the non-employee director compensation policy and vest immediately, increasing her direct holdings to 18,097 shares.

Was the AN2 Therapeutics (ANTX) Form 4 transaction a market purchase or sale?

The Form 4 shows a grant classified as an acquisition, not a market trade. Martin received 1,192 shares at $0.00 per share as compensation in stock rather than cash, under the company’s non-employee director compensation policy.

How many AN2 Therapeutics (ANTX) shares does Patricia A. Martin hold after this grant?

After the reported grant, Patricia A. Martin directly holds 18,097 shares of AN2 Therapeutics common stock. This total includes the 1,192 shares issued in lieu of cash compensation that vested immediately as disclosed in the Form 4 filing.

What is the vesting schedule for the AN2 Therapeutics (ANTX) shares granted to Patricia A. Martin?

All 1,192 shares granted to Patricia A. Martin vest immediately. The footnote explains these shares were issued in lieu of cash compensation under the non-employee director compensation policy, meaning there is no ongoing vesting schedule tied to this specific award.

Why did AN2 Therapeutics (ANTX) issue shares instead of cash to its director?

The filing states the 1,192 shares were issued in lieu of cash compensation under AN2 Therapeutics’ non-employee director compensation policy. This structure delivers director fees in stock rather than cash, aligning compensation with equity ownership in the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/10/2026 - 08:51 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Martin Patricia A.

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/10/2026		A		1,192(1)	A	$0	18,097	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy. All shares vest immediately.

	/s/ Lucy Day, Attorney-in-Fact for Patricia A. Martin	04/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)